DCF — JOHNS HOPKINS BAYVIEW MED. CTR.
Enterprise Value: $-1.7B
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-1.7B
Enterprise Value
$-520.4M
PV of Cash Flows
$-1.2B
PV of Terminal Value
$-1.9B
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $674.0M | $-112.0M | -17.0% | $-140.5M | $-127.7M |
| Year 2 | $694.2M | $-108.4M | -16.0% | $-137.8M | $-113.9M |
| Year 3 | $715.0M | $-104.5M | -15.0% | $-134.8M | $-101.2M |
| Year 4 | $736.5M | $-103.9M | -14.0% | $-135.1M | $-92.3M |
| Year 5 | $758.6M | $-105.2M | -14.0% | $-137.3M | $-85.2M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-1.7B. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$654.4M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.17113384731762854
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5